Literature DB >> 12605287

Reversal of cycloheximide-induced memory disruption by AIT-082 (Neotrofin) is modulated by, but not dependent on, adrenal hormones.

Rongzi Yan1, Quang Nguyen, James Gonzaga, Mai Johnson, Ronald F Ritzmann, Eve M Taylor.   

Abstract

RATIONALE: AIT-082 (Neotrofin), a hypoxanthine derivative, has been shown to improve memory in both animals and humans. In animals, adrenal hormones modulate the efficacy of many memory-enhancing compounds, including piracetam and tacrine (Cognex).
OBJECTIVE: To investigate the role of adrenal hormones in the memory-enhancing action of AIT-082.
METHODS: Plasma levels of adrenal hormones (corticosterone and aldosterone) in mice were significantly reduced by surgical or chemical (aminoglutethimide) adrenalectomy or significantly elevated by oral administration of corticosterone. The effects of these hormone level manipulations on the memory-enhancing activity of AIT-082 and piracetam were evaluated using a cycloheximide-induced amnesia/passive avoidance model.
RESULTS: As previously reported by others, the memory enhancing action of piracetam was abolished by adrenalectomy. In contrast, the memory enhancement by 60 mg/kg AIT-082 (IP) was unaffected. However, a sub-threshold dose of AIT-082 (0.1 mg/kg, IP) that did not improve memory in control animals did improve memory in adrenalectomized animals. These data suggested that, similar to piracetam and tacrine, the memory enhancing action of AIT-082 might be inhibited by high levels of adrenal hormones. As expected, corticosterone (30 and 100 mg/kg) inhibited the action of piracetam, however no dose up to 100 mg/kg corticosterone inhibited the activity of AIT-082.
CONCLUSIONS: These data suggest that while AIT-082 function is not dependent on adrenal hormones, it is modulated by them. That memory enhancement by AIT-082 was not inhibited by high plasma corticosterone levels may have positive implications for its clinical utility, given that many Alzheimer's disease patients have elevated plasma cortisol levels.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12605287     DOI: 10.1007/s00213-002-1350-5

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  37 in total

Review 1.  Stress and hippocampal plasticity.

Authors:  B S McEwen
Journal:  Annu Rev Neurosci       Date:  1999       Impact factor: 12.449

2.  Increased CSF cortisol in AD is a function of APOE genotype.

Authors:  E R Peskind; C W Wilkinson; E C Petrie; G D Schellenberg; M A Raskind
Journal:  Neurology       Date:  2001-04-24       Impact factor: 9.910

3.  Aldosterone receptors are involved in the mediation of the memory-enhancing effects of piracetam.

Authors:  C Mondadori; A Häusler
Journal:  Brain Res       Date:  1990-08-06       Impact factor: 3.252

4.  NMDA receptor blockers facilitate and impair learning via different mechanisms.

Authors:  C Mondadori; L Weiskrantz
Journal:  Behav Neural Biol       Date:  1993-11

Review 5.  The pharmacology of the nootropics; new insights and new questions.

Authors:  C Mondadori
Journal:  Behav Brain Res       Date:  1993-12-31       Impact factor: 3.332

Review 6.  Detrimental effects of chronic hypothalamic-pituitary-adrenal axis activation. From obesity to memory deficits.

Authors:  J Raber
Journal:  Mol Neurobiol       Date:  1998-08       Impact factor: 5.590

7.  Dexamethasone suppression test and serum prolactin in dementia disorders.

Authors:  J Balldin; C G Gottfries; I Karlsson; G Lindstedt; G Långström; J Wålinder
Journal:  Br J Psychiatry       Date:  1983-09       Impact factor: 9.319

8.  Piracetam facilitates long-term memory for a passive avoidance task in chicks through a mechanism that requires a brain corticosteroid action.

Authors:  M Loscertales; S P Rose; J N Daisley; C Sandi
Journal:  Eur J Neurosci       Date:  1998-07       Impact factor: 3.386

9.  Cortisol and Alzheimer's disease, II: Dexamethasone suppression, dementia severity, and affective symptoms.

Authors:  B S Greenwald; A A Mathé; R C Mohs; M I Levy; C A Johns; K L Davis
Journal:  Am J Psychiatry       Date:  1986-04       Impact factor: 18.112

10.  Hypothalamic dysfunction in dementia.

Authors:  C G Gottfries; J Balldin; K Blennow; G Bråne; I Karlsson; B Regland; A Wallin
Journal:  J Neural Transm Suppl       Date:  1994
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.